 Despite recent successes with monoclonal antibody checkpoint inhibitors and disappointing results from cancer vaccine trials, I believe there is potential for patient-specific vaccines to address unmet clinical needs and improve outcomes for patients who do not respond to anti-checkpoint therapy or make immune responses to their tumours.